Capricor Therapeutics Inc (NASDAQ:CAPR) has partnered with Nippon Shinyaku Co Ltd for the exclusive commercialization and distribution in the U.S of Capricor's CAP-1002 for Duchenne muscular dystrophy (DMD).
- Capricor's proprietary cell therapy, CAP-1002, comprises human allogeneic cardiosphere-derived cells.
- HOPE-Duchenne and HOPE-2, the Phase 1 and Phase 2 clinical trials of CAP-1002, showed statistically significant improvements in upper limb and/or cardiac function in the treatment groups.
- HOPE-3, the Phase 3 clinical trial that this partnership will support, will commence shortly and is expected to be the pivotal trial for CAP-1002 in DMD.
- Capricor will receive an upfront payment of $30 million with potential additional milestone payments of up to $705 million.
- Capricor will receive a double-digit percentage of revenue based on product sales.
- Price Action: CAPR shares are up 8.19% at $3.06 during the market session on the last check Tuesday.
